Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov - Ifax

MOSCOW, Dec 7: Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers, the Interfax news agency reported on Monday.

Vials labelled "COVID-19 Coronavirus Vaccine" are placed on dry ice in this illustration taken, December 4, 2020. REUTERS/Dado Ruvic/Illustration

Vials labelled "COVID-19 Coronavirus Vaccine" are placed on dry ice in this illustration taken, December 4, 2020. REUTERS/Dado Ruvic/Illustration

By Reuters

MOSCOW, Dec 7: Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers, the Interfax news agency reported on Monday.

Ad5-nCoV is a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit.

Just in

POLITICS

Being born and raised here, I share an emotional bond wi...

SPORTS

Nepal should play two series a year against test nations...

SOCIETY

Turkish Airlines aircraft overshoots, diverts to Dhaka

Republica watch

Optics and elections: How a ceremonial performance...

Commercial banks cut average deposit rate to 4.57...

Jhapa-5: Balen’s hope rest on swing votes as numbe...

More in Politics

POLITICS

NC central working committee meeting today

All central working committee office bearers and the seven provincial presidents of the party are requested to attend the meeting, he added.

POLITICS

Nepal, India sign Mutual Legal Assistance Agreement on Criminal M...

Op-Ed

Security First: What Nepal Can—and Cannot—Learn from...

From Threat Perceptions to Shared Opportunities: Tow...

Politics in the Era of Artificial Superintelligence

Voters Deserve Vision, Not Entertainment

Society

Society

Thirteen concrete, 17 suspension bridges built in Bhojpur since 2015

The Koshi Province government constructed these infrastructures across the district with substantial investment aiming to improve transportation service and enhance acc...

Society